抗VEGF治疗的1型早产儿视网膜病变中周边视网膜血管扩展的不对称性:鼻侧与颞侧半球差异
该回顾性掩蔽非随机匹配对照病例系列纳入7只接受贝伐珠单抗0.25 mg双眼治疗的1型早产儿视网膜病变眼与7只未治疗对照眼,比较鼻侧与颞侧视网膜血管扩展。结果显示治疗眼鼻侧与颞侧扩展均大于对照眼,且鼻颞扩展差异更大,提示抗VEGF在婴儿玻璃体内扩散可能不均匀。
要点
- 治疗眼鼻侧血管扩展为1.27±0.59 DD,颞侧为1.69±1.16 DD,均大于对照眼。
- 治疗组鼻颞扩展差异为0.98±0.64 DD,大于对照组的0.10±0.10 DD(P=.005)。
- 7只治疗眼中3只鼻侧扩展大于颞侧,7只对照眼中仅1只如此。
核心结论
- 接受贝伐珠单抗0.25 mg双眼治疗的1型早产儿视网膜病变眼,鼻侧与颞侧视网膜血管扩展均显著大于未治疗对照眼,且鼻颞不对称性更大。
研究设计与样本
- 回顾性、掩蔽、非随机、匹配、比较病例系列;3年内筛查382名婴儿,34名发生双侧1型早产儿视网膜病变,21名家长同意治疗。
- 治疗组为7只眼(7名婴儿)接受贝伐珠单抗0.25 mg OU;对照组为从382名筛查婴儿中按出生体重和矫正胎龄匹配后随机选取的7只无1型早产儿视网膜病变的未治疗眼(7名婴儿)。
- 纳入标准要求基线和随访(12至35天后)均有可分级100°视野眼底照片,且基线和随访时无血管化达锯齿缘的眼。
- 视网膜血管范围以像素测量从视盘边缘至颞侧或鼻侧血管边界,除以视盘直径像素得到视盘直径单位(DD),由第二位掩蔽分析者确认。
- 统计采用Mann-Whitney U检验和Wilcoxon符号秩检验。
主要发现
- 治疗眼鼻侧血管扩展为1.27±0.59 DD,对照眼为0.55±0.44 DD(P=.038)。
- 治疗眼颞侧血管扩展为1.69±1.16 DD,对照眼为0.62±0.49 DD(P=.04)。
- 治疗组鼻颞血管扩展差异为0.98±0.64 DD,对照组为0.10±0.10 DD(P=.005)。
- 鼻侧扩展大于颞侧扩展在治疗组为7只眼中的3只,对照组为7只眼中的1只。
临床怎么用
- 接受贝伐珠单抗0.25 mg治疗的1型早产儿视网膜病变眼随访中应关注鼻侧与颞侧血管扩展的不对称性。
- 研究结果提示抗VEGF在婴儿玻璃体内扩散可能不均匀,需考虑注射部位、针长、药物及分子大小差异的影响。
局限性
- 样本量有限(治疗组7只眼,对照组7只眼)。
- 为回顾性非随机研究设计。
- 随访时间较短(12至35天)。
- 作者指出需进一步研究注射部位、针长、抗VEGF药物及分子大小差异和更长随访期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Anti-vascular endothelial growth factor (anti-VEGF) therapy is an important treatment for type 1 retinopathy of prematurity (T1ROP). We previously found that regulation of VEGF signaling increased developmental vascularization into the temporal peripheral retina while reducing intravitreal neovascularization in T1ROP. To address our hypothesis that extension of retinal vascularization by early treatment with anti-VEGF could reduce T1ROP, we determined the effects of anti-VEGF therapy on retinal vascular extension in both retinal hemispheres. DESIGN: Retrospective, masked, nonrandomized, matched, comparative case series. SUBJECTS: Over 3 years, 34 of 382 screened infants developed bilateral T1ROP. Consent was obtained from parents of 21 infants for infants receiving bevacizumab 0.25 mg OU. Seven treated eyes (7 infants) had suitable imaging and were included in the treatment group. Seven untreated eyes (7 infants) without T1ROP were randomly selected after matching for birthweight and postmenstrual age from the 382 screened infants and assigned to the control group. METHODS: Infants had gradable 100° field-of-view fundus photographs of both retinal hemispheres at 2 time points: baseline before treatment, if administered, and follow-up, 12 to 35 days later. No eyes with vascularization to the ora at baseline or follow-up were included. Retinal vascular extent was measured in pixels from the optic disc margin to the temporal or nasal vascular borders and divided by the optic disc diameter in pixels to create disc diameter units (DD). Measurements were confirmed by a second masked analyst. The Mann-Whitney U test and Wilcoxon signed-rank test were used for statistical analysis. MAIN OUTCOME MEASURES: Temporal and nasal vascular extension in DD. RESULTS: Relative to control eyes, treated eyes had greater nasal (1.27 ± 0.59 vs 0.55 ± 0.44 DD; P = .038) and temporal (1.69 ± 1.16 vs 0.62 ± 0.49 DD; P = .04) extensions. There was greater disparity in vascular extension between nasal and temporal hemispheres in the treated group than in the control group (0.98 ± 0.64 vs 0.10 ± 0.10 DD; P = .005). Nasal extension was greater than temporal extension in 3 of 7 treated vs 1 of 7 control eyes. CONCLUSIONS: Treated eyes had significantly greater vascular extension in both hemispheres than control eyes, with greater nasal-temporal asymmetry. Although limited by sample size, our findings raise the question of uneven anti-VEGF diffusion in the infant vitreous. Further studies testing injection site, needle length, anti-VEGF agent, and molecular size differences and further follow-up periods are indicated.
引用
- Shah N, Chandler M, Sauer L, et al. Asymmetric Peripheral Retinal Vascular Extension in Anti-Vascular Endothelial Growth Factor-Treated Type 1 Retinopathy of Prematurity: Disparity Between Nasal and Temporal Hemispheres. Am J Ophthalmol. 2026. PMID: 42177931. doi:10.1016/j.ajo.2026.05.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。